- India's pharmaceutical company Hetero ties up with Russian Direct Investment Fund
- Sputnik V free in Russia, for other countries its price will be less than 700 rupees
India News/Covid-19 Vaccine Tracker: The Russian Direct Investment Fund (RDIF) and India's pharmaceutical company Hetero have tied up to produce Corona's vaccine Sputnik V. This agreement is to make 100 million doses every year in India. Production will start from next year.
Sputnik V has been created by the Gameleya National Research Center for Epidemiology and Microbiology of Russia. RDIF is overseeing its production and promotion abroad. The clinical trial for the third phase of the vaccine has been approved. These trials are ongoing in many countries including Belarus, UAE, Venezuela. According to IDIF, the second and third phase trials are going on in India.
More than 50 countries have requested to make 120 million doses of this vaccine. The vaccine will be produced in India, China, Brazil, South Korea and other countries for supply in the global market.
'Big step in the fight against Corona'
Murali Krishna Reddy, Director, International Marketing, Hetero Labs Ltd, said Sputnik V is most effective in treating Kovid-19. We are very pleased with this partnership with RDIF to develop the vaccine. This partnership is another step towards fulfilling our commitment and the Make in India campaign in the fight against Corona.
At the same time, RDIF CEO Kirill Dmitriev said that we are happy to announce the agreement with Hetero. This will pave the way for the production of safe and most effective corona vaccine in India. Thank you for partnering with Hetero. This will help us to increase the production capacity and provide a better solution to the people of India in this challenging period of Corona.
Hetero has over 25 years of experience
Hyderabad based company Hetero is India's leading generic pharmaceutical company. It was founded in 1993 by Dr. BPS Reddy. It is the world's largest manufacturer of anti-retroviral drugs for the treatment of HIV / AIDS. The company has over 25 years of experience in the pharmaceutical industry. Hetero's business spans 126 countries.
95% effective Sputnik vaccine
Sputnik has proven to be 95% effective in fighting corona during a trial. The second preliminary analysis of the clinical trial showed that 42 days after the first dose, it showed 95% efficacy. The data was 91.4% 28 days after the dose was given.It will also cost much less than other vaccines. People of Russia will get it for free. For other countries, its price will be less than 700 rupees.
Also Read|
No comments:
Post a Comment